Platelet-derived growth factor C is upregulated in human uterine fibroids and regulates uterine smooth muscle cell growth

Biology of Reproduction

Volumn 81, Issue 4, 2009, Pages 749-758

  Suo, Guangli ^a   Jiang, Yong ^a   Cowan, Bryan ^b   Wang, Jean Y J ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

Author keywords

Dasatinib; Imatinib; Lentivirus; PDGF receptor; ShRNAmir

Indexed keywords

LYMPHOKINE; PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PLATELET DERIVED GROWTH FACTOR C; PLATELET-DERIVED GROWTH FACTOR C; PROTEIN KINASE INHIBITOR; RECOMBINANT PROTEIN; RNA;

ADULT; ANIMAL; ARTICLE; CELL CULTURE; CELL PROLIFERATION; FEMALE; GENE EXPRESSION PROFILING; GENE SILENCING; HUMAN; LEIOMYOMA; METABOLISM; MIDDLE AGED; MOUSE; MOUSE MUTANT; MYOMETRIUM; PHYSIOLOGY; SMOOTH MUSCLE FIBER; UPREGULATION; UTERUS CANCER;

ADULT; ANIMALS; CELL PROLIFERATION; CELLS, CULTURED; FEMALE; GENE EXPRESSION PROFILING; GENE KNOCKDOWN TECHNIQUES; HUMANS; LEIOMYOMA; LYMPHOKINES; MICE; MICE, KNOCKOUT; MIDDLE AGED; MYOCYTES, SMOOTH MUSCLE; MYOMETRIUM; PLATELET-DERIVED GROWTH FACTOR; PROTEIN KINASE INHIBITORS; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR BETA; RECOMBINANT PROTEINS; RNA; UP-REGULATION; UTERINE NEOPLASMS;

EID: 74049154789     PISSN: 00063363     EISSN: 15297268     Source Type: Journal    
DOI: 10.1095/biolreprod.109.076869     Document Type: Article

References (29)

1. Day Baird D, Dunson DB, Hill MC, Cousins D, Schectman JM. High cumulative incidence of uterine leiomyoma in black and white women: ultrasound evidence. Am J Obstet Gynecol 2003; 188: 100-107.
2. Walker CL, Stewart EA. Uterine fibroids: the elephant in the room. Science 2005; 308: 1589-1592.
3. Linder D, Gartler SM. Glucose-6-phosphate dehydrogenase mosaicism: utilization as a cell marker in the study of leiomyomas. Science 1965; 150: 67-69.
4. Canevari RA, Pontes A, Rosa FE, Rainho CA, Rogatto SR. Independent clonal origin of multiple uterine leiomyomas that was determined by X chromosome inactivation and microsatellite analysis. Am J Obstet Gynecol 2005; 193: 1395-1403.
5. Blume-Jensen P, Hunter T. Oncogenic kinase signalling. Nature 2001; 411: 355-365.
6. Andrae J, Gallini R, Betsholtz C. Role of platelet-derived growth factors in physiology and medicine. Genes Dev 2008; 22: 1276-1312.
7. Hoch RV, Soriano P. Roles of PDGF in animal development. Development 2003; 130: 4769-4784.
8. Gilbertson DG, Duff ME. West JW, Kelly JD, Sheppard PO, Hofstrand PD, Gao Z, Shoemaker K, Bukowski TR, Moore M, Feldhaus AL, Humes JM, et al. Platelet-derived growth factor C (PDGF-C), a novel growth factor that binds to PDGF alpha and beta receptor. J Biol Chem 2001; 276: 27406-27414.
9. Li X, Ponten A, Aase K, Karlsson L, Abramsson A, Uutela M, Backstrom G, Hellstrom M. Bostrom H, Li H, Soriano P, Betsholtz C, et al. PDGF-C is a new protease-activated ligand for the PDGF alpha-receptor. Nat Cell Biol 2000; 2: 302-309.
10. Anderberg C, Li H, Fredriksson L, Andrae J, Betsholtz C, Li X, Eriksson U, Pietras K. Paracrine signaling by platelet-derived growth factor-CC promotes tumor growth by recruitment of cancer-associated fibroblasts. Cancer Res 2009; 69: 369-378.
11. Crawford Y, Kasman I, Yu L, Zhong C, Wu X, Modrusan Z, Kaminker J, Ferrara N. PDGF-C mediates the angiogenic and tumorigenic properties of fibroblasts associated with tumors refractory to anti-VEGF treatment. Cancer Cell 2009; 15: 21-34.
12. Reigstad LJ, Varhaug JE, Lillehaug JR. Structural and functional specificities of PDGF-C and PDGF-D, the novel members of the platelet-derived growth factors family. FEBS J 2005; 272: 5723-5741.
13. Sbinkai Y, Rathbun G, Lam KP, Oltz EM, Stewart V, Mendelsohn M, Charron J, Datta M, Young F, Stall AM, et al. RAG-2-deficient mice lack mature lymphocytes owing to inability to initiate V(D)J rearrangement. Cell 1992: 68: 855-867.
14. Sturn A, Quackenbush J, Trajanoski Z. Genesis: cluster analysis of microarray data. Bioinformatics 2002; 18: 207-208.
15. Suo G, Sadarangani A, Lamarca B, Cowan B, Wang JY. Murine xenograft model for human uterine fibroids: an in vivo imaging approach. Reproductive Sciences OnlineFirst [Internet]. 2009. Available from: http://rsx.sagepub.com/cgi/ content/abstract/1933719109336615v2.
16. Kuo C, Coquoz O, Troy TL, Xu H, Rice BW. Three-dimensional reconstruction of in vivo bioluminescent sources based on multispectral imaging. J Biomed Opt 2007; 12:024007.
17. Rice BW, Cable MD, Nelson MB. In vivo imaging of light-emitting probes. J Biomed Opt 2001; 6: 432-440.
18. Liang M, Wang H, Zhang Y, Lu S, Wang Z. Expression and functional analysis of platelet-derived growth factor in uterine leiomyomata. Cancer Biol Ther 2006; 5: 28-33.
19. Kim R, Emi M, Arihiro K. Tanabe K, Uchida Y, Toge T. Chemo-sensitization by STT571 targeting the platelet-derived growth factor/platelet-derived growth factor receptor-signaling pathway in the tumor progression and angiogenesis of gastric carcinoma. Cancer 2005; 103: 1800-1809.
20. Li L, Blumenthal DK, Masaki T, Terry CM, Cheung AK. Differential effects of imatinib on PDGF-induced proliferation and PDGF receptor signaling in human arterial and venous smooth muscle cells. J Cell Biochem 2006; 99: 1553-1563.
21. Weisberg E, Manley PW, Cowan-Jacob SW, Hochhaus A, Griffin JD. Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia. Nat Rev Cancer 2007; 7: 345-356.
22. Hwu YM, Li SH, Lee RK, Tsai YH, Yeh TS, Lin SY. Increased expression of platelet-derived growth factor C messenger ribonucleic acid in uterine leiomyomata. Fertil Steril 2008; 89: 468-471.
23. Zaitseva M, Vollenhoven BJ, Rogers PA. In vitro culture significantly alters gene expression profiles and reduces differences between myome-trial and fibroid smooth muscle cells. Mol Hum Reprod 2006; 12: 187-207.
24. Millette E, Rauch BH, Defawe O, Kenagy RD, Daum G, Clowes AW. Platelet-derived growth factor-BB-induced human smooth muscle cell proliferation depends on basic FGF release and FGFR-1 activation. Circ Res 2005; 96: 172-179.
25. Fredriksson L, Li H, Fieber C, Li X, Eriksson U. Tissue plasminogen activator is a potent activator of PDGF-CC. EMBO J 2004; 23: 3793-3802.
26. Su EJ, Fredriksson L, Geyer M, Folestad E, Cale J, Andrae J, Gao Y, Pietras K, Mann K, Yepes M, Strickland DK, Betsholtz C, et al. Activation of PDGF-CC by tissue plasminogen activator impairs blood-brain barrier integrity during ischemic stroke. Nat Med 2008; 14: 731-737.
27. Lei H, Velez G, Hovland P, Hirose T, Kazlauskas A. Plasmin is the major protease responsible for processing PDGF-C in the vitreous of patients widi proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci 2008; 49: 42-48.
28. Capdeville R, Buchdunger E, Zimmermann J, Matter A. Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat Rev Drug Discov 2002; 1: 493-502.
29. Rix U, Hantschel O, Durnberger G, Remsing Rix LL, Planyavsky M, Fernbach NV, Kaupe I, Bennett KL, Valent P, Colinge J, Kocher T, Superti-Furga G. Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets. Blood 2007; 110: 4055-11063